December 15th, 2015

Theralase to Present at AlphaNorth Capital Conference

TORONTO, ON / ACCESSWIRE / January 12, 2016 / Theralase Technologies Inc. ("Theralase" or the "Company") (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will be presenting to investors at the AlphaNorth Capital Conference held at the Atlantis Resort in Bahamas, from January 15th to 17th, 2016.

The 3rd annual conference features some of the best small cap innovators in the technology, biotech and healthcare spaces and connects them with the top institutional and specialist brokers in North America through a full day series of one-on-one meetings.

Roger Dumoulin-White, President and CEO, stated that, "The AlphaNorth conference provides the Company with an opportunity to present the Theralase corporate vision, its recent successes and upcoming milestones that will drive shareholder value, to a comprehensive audience of retail and institutional investors in well organized, private meetings.

Theralase has been very successful in executing on its strategic objectives in 2015 by completing:

- Health Canada approval of its next generation TLC-2000 Therapeutic Medical Laser System
- US Food and Drug Administration approval of the TLC-2000
- Health Canada Clinical Trial Application approval
- University Health Network Research Ethics Board approval

and is currently awaiting Health Canada Investigational Testing Authorization approval of the TLD-3200 medical laser, expected in 1Q2016, to commence a Phase Ib clinical trial on patients inflicted with Non-Muscle Invasive Bladder Cancer.

2016 will be an exciting year as the Company dramatically grows its revenues through sales of the TLC-2000 next generation therapeutic laser to healthcare practitioners throughout Canada and the US. In addition, the Company plans to successfully complete a "first-in-man" Phase Ib clinical trial using its state-of-the-art Photo Dynamic Therapy aimed at proving the safety, tolerability and as an exploratory objective efficacy in the destruction of bladder cancer."

About Theralase Technologies Inc.

Theralase Technologies Inc. ("Theralase(R)") (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase's Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at and .

Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225

SOURCE: Theralase Technologies Inc.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.